磁共振成像（MRI）、超声和荧光成像等医学成像方式在肿瘤诊断的临床实践中已获得广泛接受。每种成像模式都有其独特的原理、优点和局限性，因此需要采用多模式方法来全面了解疾病过程。为了提高诊断精度，医生经常整合多种成像模式的数据，推动多模式成像技术研究的进步。在本研究中，通过开环聚合制备了血卟啉-聚乳酸（HP-PLLA）聚合物，并对其进行了全面表征使用 FT-IR、1H-NMR、XRD 和 TGA。通过乳液-溶剂蒸发制备了封装全氟戊烷（PFP）和水杨酸的 HP-PLLA 纳米颗粒。使用 DLS 和 TEM 评估 Zeta 电位和平均直径。通过细胞迁移、溶血和细胞毒性测定评估生物相容性。超声成像采用专用设备进行，CEST MRI采用7.0T动物扫描仪进行。我们设计并制备了一种新型双模式纳米成像探针SA/PFP@HP-PLLA NPs。 PFP 增强了 US 成像，而水杨酸则增强了 CEST 成像。平均尺寸为74.43±1.12 nm，多分散指数为0.175±0.015，表面zeta电位为-64.1±2.11 mV。这些纳米粒子表现出优异的生物相容性和稳定性。体外和体内实验均证实了 SA/PFP@HP-PLLA NP 改善肿瘤表征和诊断精度的能力。SA/PFP@HP-PLLA NP 表现出有前景的双模态成像能力，表明其在临床前和临床中的潜力用作造影剂。© 2024 Ding et al.

Medical imaging modalities, such as magnetic resonance imaging (MRI), ultrasound, and fluorescence imaging, have gained widespread acceptance in clinical practice for tumor diagnosis. Each imaging modality has its own unique principles, advantages, and limitations, thus necessitating a multimodal approach for a comprehensive disease understanding of the disease process. To enhance diagnostic precision, physicians frequently integrate data from multiple imaging modalities, driving research advancements in multimodal imaging technology research.In this study, hematoporphyrin-poly (lactic acid) (HP-PLLA) polymer was prepared via ring-opening polymerization and thoroughly characterized using FT-IR, 1H-NMR, XRD, and TGA. HP-PLLA based nanoparticles encapsulating perfluoropentane (PFP) and salicylic acid were prepared via emulsion-solvent evaporation. Zeta potential and mean diameter were assessed using DLS and TEM. Biocompatibility was evaluated via cell migration, hemolysis, and cytotoxicity assays. Ultrasonic imaging was performed with a dedicated apparatus, while CEST MRI was conducted using a 7.0 T animal scanner.We designed and prepared a novel dual-mode nanoimaging probe SA/PFP@HP-PLLA NPs. PFP enhanced US imaging, while salicylic acid bolstered CEST imaging. With an average size of 74.43 ± 1.12 nm, a polydispersity index of 0.175 ± 0.015, and a surface zeta potential of -64.1 ± 2.11 mV. These NPs exhibit excellent biocompatibility and stability. Both in vitro and in vivo experiments confirmed the SA/PFP@HP-PLLA NP's ability to improve tumor characterization and diagnostic precision.The SA/PFP@HP-PLLA NPs demonstrate promising dual-modality imaging capabilities, indicating their potential for preclinical and clinical use as a contrast agent.© 2024 Ding et al.